This review summarises and discusses the final results from a long-term, prospective, observational, multicentre study in patients with aHUS who participated in any of five parent eculizumab trials.
Independent commentary is provided by Associate Professor David Mudge, a consultant nephrologist at Princess Alexandra Hospital in Brisbane.
Please login below to download this issue (PDF)